Abiomed obtains FDA approval for cardiac device
Cardiac medical devices company Abiomed, Inc. (Nasdaq:ABMD) said this morning that it received clearance from the U.S. Food and Drug Administration for its Impella 2.5 Cardiac Assist Device. The approval enables Abiomed to begin selling the device to an estimated 14,000 interventional cardiologists at roughly 1,700 heart hospitals in the United States.
Shares gained 4.5%, or $0.67, to $15.45 in pre-market trading. For detailed price information and recent news stories about Abiomed, click ABMD.
